Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently...
Hence then, the article about vicebio next generation vaccine biotech to be acquired by sanofi for us 1 6 billion was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion )
Also on site :
- ‘The Princess Bride’ Star Cary Elwes Shares Tribute to Rob Reiner: ‘From That Very First Meeting I Fell In Love With Him’
- A Shockingly Recent Year Just Cracked the Top 5 of Rock's Most Legendary Years
- SFM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Sprouts Farmers Market, Inc. (SFM) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit